IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Advanced Solid Malignancies
AstraZenecamonoclonal_antibodyPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
26 Active assets in the Advanced Solid Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Durvalumab AstraZeneca | Phase 3 | B |
FULVESTRANT Carrick Therapeutics Limited | Phase 1/2 | B |
prj1-3024 Zhuhai Yufan Biotechnologies Co., Ltd | Phase 1/2 | CCC |
Encequidar Hanmi Pharmaceutical Company Limited | Phase 1 | CCC |
Irinotecan Hanmi Pharmaceutical Company Limited | Phase 1 | CCC |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →